Sarepta Therapeutics Stock News

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.

Beam Therapeutics develops highly promising base-editing therapies. CRISPR Therapeutics could soon have its first product on the market in the U.S. Sarepta Therapeutics is a leader in treating rare ge

The recent surge in official interest rates, the most substantial in 40 years, is anticipated to impact aggregate demand significantly. This could potentially result in a GDP reduction of approximatel

Sarepta Therapeutics (SRPT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions cou

Hosted by Brian Sullivan, “Last Call” is a fast-paced, entertaining business show that explores the intersection of money, culture and policy. Tune in Monday through Friday at 7 p.m.

Sarepta released results of its phase 3 trials last week for Elevidys, which fell short of expectations. The company, however, remains optimistic that a label expansion for its gene therapy remains po

Not all technology companies are the same. In fact, not all chipmakers are the same.

Sarepta Therapeutics' gene therapy, Elevidys, faces an uphill regulatory journey, analysts said Tuesday on mixed test results.

Sarepta's DMD drug Elevidys failed to meet the primary endpoint in a phase 3 study. However, the company plans to pursue an expanded label for the drug anyway.

Stocks are down today and investors wondering why have come to the right place as we have an answer to that question! Several factors are weighing on the stock market and keeping shares down today.

Sarepta Therapeutics (NASDAQ: SRPT ) stock is taking a beating on Tuesday after the biopharmaceutical company announced results from a Phase 3 clinical trial. That clinical trial covers the use of ELE

Sarepta Therapeutics shares fell over 42% in premarket trading on Tuesday, after its gene therapy for a progressive muscle-wasting disorder failed to meet the main goal in a trial that was key to the

In a gene therapy study for patients with Duchenne muscular dystrophy, the primary endpoint was not met.

Sarepta unveiled mixed results late Monday for a gene therapy that targets a muscle-wasting disease in boys. SRPT stock was halted.